FDA has approved Tecvayli (teclistamab-cqyv) plus Darzalez Faspro (daratumumab and hyaluronidase-fihj) for the treatment of adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent.
Five years ago, Tyler Jacks took on a new challenge, becoming president of Break Through Cancer, a foundation that has pledged to spend at least $500 million to support research projects across top tier cancer centers.
